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Abstract
Background: To determine whether botulinum toxin treatment history affected the outcomes of a study comparing the safety and efficacy of
incobotulinumtoxinA with placebo in subjects with cervical dystonia (CD).
Methods: This was a prospective, double-blind, randomized, placebo-controlled, multicenter trial in botulinum toxin-treated or toxin-naı¨ve CD subjects. Subjects
received a fixed dose of either 120 U or 240 U of incobotulinumtoxinA or placebo. The primary outcome measure was change from baseline to Week 4 in the
Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total score. Treatment-emergent adverse events (TEAEs) were also evaluated. This report
represents a subgroup analysis of botulinum toxin-treated or toxin-naı¨ve subjects.
Results: Participants (N5233; 38.6% toxin-naı¨ve) had a mean age of 52.8 years. IncobotulinumtoxinA significantly improved TWSTRS total scores from baseline to
Week 4 in both dose groups versus placebo, and the improvement persisted through the end of the study (#20 weeks). Both the previously toxin-treated and toxin-naı¨ve
subjects demonstrated significant improvements in TWSTRS total scores at Week 4 compared to baseline. The most frequent TEAEs in the incobotulinumtoxinA
groups were dysphagia, neck pain, and muscular weakness, which were generally mild. TEAEs were more common in the 240 U group and toxin-naı¨ve subjects.
Discussion: Overall, incobotulinumtoxinA was safe and effective in CD, regardless of toxin therapy history. A lower starting dose may be better tolerated among
toxin-naı¨ve subjects without sacrificing efficacy.
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Introduction
Cervical dystonia (CD), the most common focal form of dystonia,1 is
marked by contractions of neck and shoulder musculature that affect
head motion and posture.2,3 Up to three-fourths of patients experience
pain, which is an important cause of disability.2,4 Class A evidence has
established botulinum toxin treatment as an effective means of controlling
CD symptoms.3 IncobotulinumtoxinA (marketed as XEOMINH in the
United States, Canada, and Europe; Merz Pharmaceuticals, GmbH,
Frankfurt, Germany) is a botulinum toxin serotype A that differs from
other available formulations in that the botulinum toxin complex is
purified from the culture supernatant, and the active ingredient is then
separated from accessory (complexing) proteins (hemagglutinins and non-
hemagglutinins) through a series of steps, yielding only the active
neurotoxin (molecular weight of 150 kDa).5,6
The specific aim of this report is to compare symptom improvement and
tolerability associated with a single injection of incobotulinumtoxinA for
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CD in subjects with and without a history of botulinum toxin therapy. This
report is a subgroup analysis of the previously published full clinical trial.7
Methods
This was a prospective, multicenter, double-blind, randomized,
placebo-controlled study conducted at 37 sites in the United States. The
primary outcome of this study has been previously reported by Comella
and colleagues.7 Each site’s Institutional Review Board approved the
study protocol and the informed consent process. The study was
conducted in accordance with the ethical principles outlined in the
Declaration of Helsinki and is consistent with Good Clinical Practice
and the applicable regulatory requirements. Prior to screening, all
subjects provided written informed consent. The study was registered
with clinicaltrials.gov (Identification number: NCT00407030).
Study subjects. All subjects were outpatients age 18 to 75 years
old with a clinical diagnosis of primary CD of predominantly
rotational form, a Toronto Western Spasmodic Torticollis Rating
Scale (TWSTRS)8,9 total score >20 (out of 85), a TWSTRS severity
subscore >10 (out of 35), a TWSTRS disability subscore >3 (out of
30), and a TWSTRS pain subscore >1 (out of 20). Subjects previously
treated with botulinum toxin were eligible if the last two injection
sessions were adequately documented, the therapeutic response had
been stable, and at least 10 weeks had passed since the most recent
session. Secondary non-responders to botulinum toxin type A or B
were excluded, and subjects were excluded if they had been previously
treated with incobotulinumtoxinA. Further details of the inclusion/
exclusion criteria are provided in the full clinical trial.7
Randomization, study drug, and visits. Subjects were
randomly allocated to equal-sized groups for a single intramuscular
injection session of placebo or of a fixed total dosage of 120 U or 240 U
incobotulinumtoxinA. (For additional details, see the full published
clinical trial.7)
Efficacy assessments. The primary efficacy measure was the
change in TWSTRS total score at 4 weeks compared with baseline.
Secondary efficacy measures included change in TWSTRS total score
at 8 weeks and the final visit; change in TWSTRS severity, disability,
and pain subscores at 4 and 8 weeks after injection and at the final
visit; and a global self-assessment of efficacy as rated by each subject on
a nine-point scale10 at their final visit.7 (For additional details, see the
full published clinical trial.7)
Safety assessments. Adverse events were evaluated during each
visit and telephone contact. (For additional details, see the full
published clinical trial.7)
Statistical analyses. A total of 222 subjects was planned,
including at least 87 (or approximately 40%) who were naı¨ve to
botulinum toxin therapy. Previously reported comparisons between
treatment groups were performed by using a fixed sequence test
procedure (step downward) in the intent to treat (ITT) population.
This procedure negates the need for type I error adjustment, and all
tests of the fixed sequence test procedure were performed two-sided
with a type-1 error of a50.05.7 (See the full published clinical trial for
additional details.7)
For efficacy outcomes, subgroup analyses of previously treated
versus toxin-naı¨ve subjects were subjected to analysis of covariance
(ANCOVA), log-rank or Mann-Whitney test, as appropriate. The
analyses included in this manuscript were pre-planned and included in
the statistical analysis plan; however, it is important to note that this
study was not powered to detect differences between the two
subgroups (i.e., previously treated versus toxin-naı¨ve subjects).
Results
Baseline characteristics and subject disposition. Subjects’
baseline characteristics are summarized by treatment group and
treatment history in Table 1. The median CD duration (time since first
symptoms) and the median time since first diagnosis were shorter for
toxin-naı¨ve than for previously treated subjects. Across all treatment
groups, toxin-naı¨ve subjects were slightly younger than previously
treated subjects.
Of the 301 subjects screened, 233 were randomized to treatment
(ITT population), including 90 subjects (38.6%) who were naı¨ve to
botulinum toxin treatment. In all, 81 (34.8%) subjects were injected
with 240 U, 78 (33.5%) with 120 U, and 74 (31.8%) with placebo.
Subject disposition throughout the study is diagrammed in Figure 1.
Among ITT subjects, 219 (94.0%) completed the study. Among the
233 subjects in the ITT population, 18 subjects had one or more major
protocol deviations, most often concerning study medication admin-
istration (seven subjects), leaving a treated-per-protocol (TPP) popula-
tion of 215 subjects.
Previously treated subjects at the most recent session had received a
mean toxin dose of 225 U of onabotulinumtoxinA, 530 U of
abobotulinumtoxinA, or 10,875 U of rimabotulinumtoxinB. A total
of 85% had been previously treated with onabotulinumtoxinA. Most
previously treated subjects (65.3%) had received high doses of
botulinum toxin (.180 U of onabotulinumtoxinA, .12,000 U of
rimabotulinumtoxinB, or .540 U of abobotulinumtoxinA) prior to
entering the trial (Table 1).
Efficacy.
Overall. The mean (SD) decrease (improvement) in TWSTRS total
score from baseline to Week 4 in the ITT population was –10.9 (11.7)
points in the 240 U group and –9.9 (10.4) in the 120 U group, versus –
2.2 (7.3) in the placebo group (p , 0.001 for each comparison with
placebo, and p5 0.447 for comparison of the two dose groups).7 For
additional details, see the full published clinical trial.7
Toxin-Naı¨ve versus Placebo. Among toxin-naı¨ve subjects, the mean
improvements in TWSTRS total score at Week 4, Week 8, and the
final visit was superior to that for placebo at all time points for both
dose groups (Table 2 and Figure 2a).
Previously Treated versus Placebo. Among previously treated subjects,
the mean improvements in TWSTRS total score at Week 4, Week 8,
and the final visit was superior to that for placebo at all time points for
both dose groups (Table 2 and Figure 2b).
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Sex, n (% of subgroup)
Females 21 (67.7) 30 (63.8) 23 (74.2) 31 (62.0) 17 (60.7) 32 (69.6)
Males 10 (32.3) 17 (36.2) 8 (25.8) 19 (38.0) 11 (39.3) 14 (30.4)
Age, mean (SD) 50.9 (11.9) 54.0 (11.2) 50.9 (12.1) 54.7 (12.1) 51.5 (10.5) 53.0 (11)
Race, n (% of subgroup)
White 31 (100) 43 (91.5) 28 (90.3) 46 (92.0) 24 (85.7) 41 (89.1)
Hispanic or Latino 0 3 (6.4) 2 (6.5) 3 (6.0) 2 (7.1) 0
Black 0 0 1 (3.2) 1 (2.0) 2 (7.1) 2 (4.3)
Other 0 1 (2.1) 0 0 0 3 (6.5)
Weight (lb), median 161.9 191.0 158.1 161.0 165.0 164.0
BMI (kg/m2), median 24.7 28.7 24.7 24.3 27.4 26.8
Estimated duration of CD
(months), median
72.0 92.0 60.0 102.0 60.0 122.5
Toxin injections since first
diagnosis, (number) mean (SD)
n/a 13.3 (12.4) n/a 17.7 (17.1) n/a 15.5 (11.4)
Time since most recent toxin
injection (months), median
n/a 3.6 n/a 4.0 n/a 3.9
Botulinum toxin type and mean doses of last injection prior to study entry
OnabotulinumtoxinA
Mean (SD) 219.4 (74.4) 222.8 (78.3) 232.5 (72.4)
# 120 U n/a 7 (17.5) n/a 6 (14.0) n/a 4 (10.5)
. 120 U to 180 U n/a 3 (7.5) n/a 3 (7.0) n/a 4 (10.5)
. 180 U n/a 30 (75.0) n/a 34 (79.1) n/a 30 (79.0)
RimabotulinumtoxinB
Mean (SD) 12000 (500) 10875 (2250.0) 10200 (2049.4)
# 6,000 U n/a 0 n/a 0 n/a 0
. 6,000 U to 12,000 U n/a 2 (66.7) n/a 4 (100.0) n/a 5 (100.0)
. 12,000 U n/a 1 (33.3) n/a 0 n/a 0
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Previously Treated versus Naı¨ve. In the 120 U group, previously
treated subjects showed a steeper, step-wise deterioration in their mean
TWSTRS total score from baseline to month-to-month post-treatment
(–8.5 points at Week 4, –3.8 at Week 8, and –1.8 at the final visit)
compared to the treatment-naı¨ve subjects, who showed a lesser degree of
deterioration from month-to-month post-treatment (–11.9 and Week 4;
28.0 at Week 8, and26.3 points at the final visit). Similarly for the 240
U group, the deterioration in the mean TWSTRS total score from
baseline was gradual and step-wise from month-to-month for previously
treated subjects ( –11.4 points at Week 4, –8.3 at Week 8, and –4.8 at the
final visit), whereas deterioration in the mean TWSTRS total score























Mean (SD) 500 (0) 550 (409.3) –
# 360 U n/a 0 n/a 1 (33.3) n/a 0
. 360 U to 540 U n/a 2 (100) n/a 1 (33.3) n/a 0
. 540 U n/a 0 n/a 1 (33.3) n/a 0
Frequencies and percentages are based on non-missing values.
Abbreviations: CD, cervical dystonia; ITT, intent to treat; N/n, total subject population/subset of total subject population; %, percentage; SD, standard deviation;
U, Units.
Figure 1. Subject Disposition.
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TWSTRS Scores: Baseline Values and 4-Week Change by Treatment Group and Treatment History
(ITT Population; missing values replaced by baseline values)
TWSTRS Total Score
Baseline, mean (SD) 41.9 (9.7) 43.1 (9.7) 40.1 (9.2) 43.4 (9.3) 41.3 (6.5) 42.0 (8.7)
D at Week 4, mean (SD) 211.9 (11.1) 28.5 (9.7) 210.0 (9.2) 211.4 (13.1) 22.0 (6.0) 22.4 (8.1)
p-value (ANCOVA)
Treatment vs. Placebo ,0.001 0.002 ,0.001 ,0.001 n/a n/a
120 U vs. 240 U 0.405 0.135 n/a n/a n/a n/a
TWSTRS Severity Score
Baseline, mean (SD) 17.2 (4.8) 18.6 (4.0) 17.1 (3.8) 19.6 (3.9) 18.1 (3.3) 19.3 (3.5)
D at Week 4, mean (SD) 24.1 (4.3) 23.7 (4.4) 25.4 (5.5) 25.6 (6.4) 21.9 (4.5) 21.9 (3.7)
p-value (ANCOVA)
Treatment vs. Placebo 0.075 0.051 0.011 ,0.001 n/a n/a
120 U vs. 240 U 0.349 0.071 n/a n/a n/a n/a
TWSTRS Disability Score
Baseline, mean (SD) 12.5 (5.2) 13.4 (3.9) 12.0 (4.6) 12.8 (4.7) 11.9 (3.1) 11.7 (4.4)
D at Week 4, mean (SD) 24.3 (5.9) 22.6 (3.7) 23.0 (4.0) 23.0 (4.6) 0.4 (3.0) 20.2 (3.6)
p-value (ANCOVA)
Treatment vs. Placebo ,0.001 0.015 0.001 0.001 n/a n/a
120 U vs. 240 U 0.183 0.424 n/a n/a n/a n/a
TWSTRS Pain Score
Baseline, mean (SD) 12.2 (3.8) 11.1 (4.1) 10.9 (4.4) 11.0 (3.7) 11.2 (3.8) 11.0 (3.8)
D at Week 4, mean (SD) 23.5 (4.0) 22.2 (4.9) 21.6 (4.6) 22.9 (4.2) 20.4 (2.8) 20.3 (3.1)
p-value (ANCOVA)
Treatment vs. Placebo 0.006 0.035 0.185 ,0.001 n/a n/a
120 U vs. 240 U 0.215 0.397 n/a n/a n/a n/a
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not in the first 2 months (–10.0 points at Week 4, –11.6 at Week 8, and
–4.2 at the final visit).
Safety. Overall, AEs occurred in 56.8% of the 240 U group,
55.1% of the 120 U group, and 45.9% of the placebo group, making
their incidence higher for active treatment than for placebo but with
little difference between dosages. Among subjects receiving active
treatment, the incidence of AEs was numerically higher in toxin-naı¨ve
than in previously treated subjects in the 240 U group (Table 3). The
AE incidence in the 120 U group was lower in the toxin-naı¨ve group
than in the previously treated group. In toxin-naı¨ve subjects, the
incidence of AEs increased with dose. Muscular weakness and neck
pain were more common in toxin-naı¨ve than in previously treated
subjects in the 240 U group. Dysphagia was the most common AE
(active treatment . placebo, 240 U . 120 U, toxin-naı¨ve .
previously treated subjects). However, the investigators’ assessments
of global treatment tolerability performed by IGAT at each subject’s










































Global Response Rating +2.0 +0.9 +1.4 +1.3 +0.3 20.4
p-value (ANCOVA)
Treatment vs. Placebo ,0.001 ,0.001 0.009 ,0.001 n/a n/a
120 U vs. 240 U 0.101 0.228 n/a n/a n/a n/a
Subject evaluation of global response scores: +4, complete abolishment of all signs and symptoms; +3, marked improvement; +2, moderate improvement; +1, slight
improvement; 0, unchanged; 21, slight worsening; 22, moderate worsening; 23, marked worsening; 24, very marked worsening.
p-value: Analysis of Covariance (ANCOVA) based upon the Full Treatment Model.
Abbreviations: D, change; ITT, intent to treat; N/n, total subject population/subset of total subject population; %, percentage; SD, standard deviation; U, units.
Figure 2. Mean changes in TWSTRS Total Score, by Treatment Group and Treatment History. Figure 2A. Toxin-Naı¨ve Subjects. Figure 2B. Previously
Toxin-Treated Subjects. ap,0.05 treatment group versus placebo; bp.0.05 120 U versus 240 U; cp,0.05 120 U versus 240 U; p-value: Analysis of Covariance
(ANCOVA) – change from baseline in TWSTRS total score; missing values replaced by baseline value [full model].
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Four serious AEs occurred in the 240 U group (three in toxin-naı¨ve
subjects and one in a previously treated subject). The events were
staphylococcal infection, appendicitis, asthma, and chronic obstructive
pulmonary disease, which were all judged to be unrelated to the trial
medication. AEs leading to discontinuation occurred in three subjects,
two of whom were toxin-naı¨ve recipients of 240 U. One of them
experienced musculoskeletal pain, neck pain, and muscle weakness,
and the other experienced muscle weakness. The third was a
previously treated recipient of 120 U who experienced nausea and
dizziness.
Discussion
Regardless of toxin treatment history, an injection session of
incobotulinumtoxinA was effective in subjects with CD in both dose





















Any TEAE 17 (54.8) 26 (55.3) 22 (71.0) 24 (48.0) 16 (5.71) 18 (39.1)
Any adverse drug reaction 12 (38.7) 16 (34.0) 18 (58.1) 11 (22.0) 7 (25.0) 4 (8.7)
Any serious TEAE 1 (3.2) 3 (6.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Any TEAE leading to
discontinuation
0 (0.0) 1 (2.1) 2 (6.5) 0 (0.0) 0 (0.0) 0 (0.0)
Treatment Emergent AEs by MEDRA1 preferred term in > 5% of subjects in any treatment group
Dysphagia2 5 (16.1) 4 (8.5) 7 (22.6) 8 (16.0) 0 (0.0) 2 (4.3)
Neck pain 1 (3.2) 3 (6.4) 7 (22.6) 5 (10.0) 1 (3.6) 2 (4.3)
Muscular weakness 2 (6.5) 3 (6.4) 7 (22.6) 2 (4.0) 1 (3.6) 0 (0.0)
Injection site pain 3 (9.7) 4 (8.5) 2 (6.5) 1 (2.0) 4 (14.3) 0 (0.0)
Musculoskeletal pain 3 (9.7) 3 (6.4) 2 (6.5) 1 (2.0) 0 (0.0) 1 (2.2)
Headache 0 (0.0) 3 (6.4) 2 (6.5) 2 (4.0) 3 (10.7) 0 (0.0)
Nausea 0 (0.0) 2 (4.3) 3 (9.7) 1 (2.0) 0 (0.0) 0 (0.0)
Musculoskeletal stiffness 1 (3.2) 0 (0.0) 3 (9.7) 1 (2.0) 1 (3.6) 0 (0.0)
Sinusitis 2 (6.5) 0 (0.0) 2 (6.5) 1 (2.0) 0 (0.0) 2 (4.3)
Muscle spasms 0 (0.0) 1 (2.1) 2 (6.5) 1 (2.0) 1 (3.6) 1 (2.2)
Pharyngolaryngeal pain 0 (0.0) 2 (4.3) 1 (3.2) 1 (2.0) 2 (7.1) 0 (0.0)
Myalgia 1 (3.2) 0 (0.0) 2 (6.5) 0 (0.0) 0 (0.0) 0 (0.0)
Nasopharyngitis 1 (3.2) 2 (4.3) 0 (0.0) 0 (0.0) 0 (0.0) 5 (10.9)
Pain in extremity 0 (0.0) 0 (0.0) 0 (0.0) 3 (6.0) 0 (0.0) 0 (0.0)
Paresthesia 0 (0.0) 0 (0.0) 2 (6.5) 0 (0.0) 0 (0.0) 0 (0.0)
Toothache 2 (6.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
1Medical Dictionary for Regulatory Activities, version 9.1. The AE types shown are those that affected >5% of any subgroup and are listed in descending order of
frequency among all active-treatment recipients.
2Subjects were specifically asked to report any swallowing difficulties using a 5-point dysphagia scale.
Abbreviations: N/n, total subject population/subset of total subject population; %, percentage; U, units.
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groups. Based on the primary outcome measure (TWSTRS total
score), both the 120 U and 240 U doses produced significant
improvement compared with placebo as assessed at 4 weeks among
previously treated and toxin-naı¨ve subjects. Regardless of toxin
treatment history, incobotulinumtoxinA was well tolerated. Although
our study was not powered to detect a difference between the two
active treatment groups, several themes emerge from these subgroup
post-hoc analyses.
First, previously treated subjects – whose history included a mean of
more than 15 injection sessions and a mean toxin dose, at the most
recent session, of 224.7 U of onabotulinumtoxinA or 10,875 U of
rimabotulinumtoxinB – tended to have a more pronounced response
on most efficacy measures with the 240 U dose, whereas this trend was
not apparent among toxin-naı¨ve subjects. For example, the mean
4-week improvement among previously treated subjects was 11.4
points on the TWSTRS total score in the 240 U group and 8.5 points
in the 120 U group. This result is not surprising given that many of the
subjects randomized to the 120 U group received about half of their
normal dose. In contrast, this trend was not noted among toxin-naı¨ve
subjects. By several measures – TWSTRS total score at all time points,
disability and pain subscores at 4 weeks, and patient ratings of global
improvement – the response was more pronounced at the lower dose.
However, these differences did not reach statistical significance.
Therefore, there was no added benefit of the higher dose among
toxin-naı¨ve subjects compared to previously treated subjects. These
findings support current recommendations in clinical practice of
initiating botulinum toxin treatment at lower dosages in naı¨ve patients
and then optimizing the dose during follow-up treatment.
Second, the superiority of 240 U over 120 U in improving the mean
total TWSTRS score was mostly due to the severity subscale rather
than the disability and pain subscale. It is therefore possible that the
toxin dose required to reduce pain and disability may not be as high as
the dose required to further improve the degree of neck, chin and
shoulder displacement (as measured in the severity subscale).
Third, AEs were more common in the toxin-naı¨ve subgroup
compared to the previously treated subgroup, especially in
incobotulinumtoxinA 240 U patients (71% versus 48%, respectively);
whereas the overall AEs were similar in the incobotulinumtoxinA 120
U group patients (55% versus 55%, respectively). The explanation may
lie in an increased tolerance among patients repeatedly treated with a
medication, which in turn may be related to factors including changes
in physiologic response. In this study, there was a double-blind
extension in which the highest incidences of AEs were observed during
the first injection interval.11 Incidences of AEs tended to decrease with
subsequent injections or remained at constant levels throughout the
double-blind extension, suggesting that there was no cumulative effect.
As alternative explanations to the development of tolerance, there might
have been a treatment-group bias in attentiveness to events (i.e., the
previously treated group may have become familiar with AEs and may no
longer be concerned with their symptoms compared with the toxin-naı¨ve
group, thereby affecting reporting patterns). An additional bias, seen in the
context of clinical trials, is that patients who have previously experienced
adverse reactions to toxin treatments are less likely to volunteer as subjects.
In any case, no evidence of new, unexpected AEs observed. Overall,
incobotulinumtoxinA was effective and safe in the treatment of CD,
regardless of botulinum toxin treatment history, as assessed using the
primary outcome of TWSTRS total score 4 weeks after injection.
It should be noted that subjects received fixed doses of
incobotulinumtoxinA in order to meet the regulatory authority-
specified requirements. Thus, the study design does not reflect the
doses typically used in clinical practice. Botulinum toxin dosing should
be individualized to meet a patient’s needs while also taking into
account the patient’s botulinum toxin treatment history.
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